RxDoctor Payments DataLook up a doctor →

Audra McCall, PA

Physician Assistant · Broken Arrow, OKNPI 1306845524

Payments from drug & device makers

$8,635in general payments, 2019–2025

Across 404 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$906
  • Johnson & Johnson$757
  • AstraZeneca$711
  • Pfizer$430
  • Neurocrine Biosciences, Inc.$357
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$8,635100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,635 in reported general payments places this provider in the 95th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$26,632
Medicare patients
159
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$50,607
Invega SustennaPaliperidone Palmitate12$38,226
VraylarCariprazine Hcl18$26,885
MounjaroTirzepatide20$22,538
Soliqua 100-33Insulin Glargine/Lixisenatide23$19,989
KerendiaFinerenone12$14,268
XareltoRivaroxaban18$13,388
EliquisApixaban14$11,125
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$11,062
Rosuvastatin Calcium44$2,515
SynthroidLevothyroxine Sodium14$1,433
Losartan Potassium68$980
Metoprolol Succinate37$945
Estradiol21$640
Omeprazole26$576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$757$51,61430 claims
Novo NordiskOzempic$107$50,60736 claims
AbbVieVraylar, Synthroid$1,072$28,31832 claims
Lilly USA, LLCMounjaro, Olanzapine$906$22,74432 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$186$19,98923 claims
BayerKerendia$227$14,26812 claims
PfizerEliquis$430$11,12514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Broken Arrow

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →